Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers

Although fatigue is a common symptom in multiple sclerosis (MS), its pathomechanisms are incompletely understood. Glatiramer acetate (GA), an immunomodulatory agent approved for treatment of relapsing-remitting MS (RRMS), possesses unique mechanisms of action and has been shown to exhibit beneficial...

詳細記述

書誌詳細

主要な著者:	Oliver Neuhaus, Wolfgang Köhler, Florian Then Bergh, Wolfgang Kristoferitsch, Jürgen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2021-03-01
シリーズ:	Biomolecules
主題:	multiple sclerosis fatigue glatiramer acetate
オンライン･アクセス:	https://www.mdpi.com/2218-273X/11/3/393
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!